美国支气管镜肺减容术住院并发症发生率
该研究利用美国全国住院患者样本数据库,分析2018至2020年467例BLVR相关住院的并发症。结果显示气胸发生率26.3%,急性呼吸衰竭19.5%,COPD急性加重8.8%,肺炎7.3%,咯血5.3%;气胸患者中68.3%需置入胸管,14.8%需移除支气管内活瓣。住院中位时长2.8天,住院死亡少于11例(<2.3%)。作者认为真实世界并发症率与早期随机对照试验相似,BLVR是重度肺气肿的安全治疗选择。
要点
- BLVR术后气胸发生率26.3%,其中68.3%(84/123)需置入胸管,是急诊和ICU需重点识别和处理的并发症。
- 急性呼吸衰竭发生率19.5%,COPD急性加重8.8%,肺炎7.3%,咯血5.3%,提示术后呼吸系统并发症常见。
- 14.8%的患者需移除支气管内活瓣,住院中位时长2.8天,住院死亡少于11例(<2.3%)。
- 2019年至2020年BLVR手术量从153例增至295例,翻倍,提示临床应用增加。
- 发生住院并发症的亚组在合并症、人口学特征和医院特征方面与无并发症组无显著差异。
适用人群与场景
- 美国全国住院患者样本数据库中2018至2020年接受BLVR手术的住院患者。
- 中位年龄67.9岁(四分位距61.1-72.8岁),女性210例(45.0%),白人401例(85.8%),Medicare为主要支付方(72.8%)。
- 多数手术在城市教学医院进行(56.9%)。
红旗征与不能漏的情况
- 气胸:发生率26.3%,其中68.3%(84/123)需置入胸管。
- 急性呼吸衰竭:发生率19.5%。
- COPD急性加重:发生率8.8%。
- 肺炎:发生率7.3%。
- 咯血:发生率5.3%。
- 需移除支气管内活瓣:14.8%。
研究设计与关键结果
- 研究类型:基于美国全国住院患者样本数据库的回顾性分析,纳入2018至2020年467例BLVR相关住院。
- 手术量:2019年至2020年BLVR手术量从153例增至295例,翻倍。
- 主要并发症率:气胸26.3%,急性呼吸衰竭19.5%,COPD急性加重8.8%,肺炎7.3%,咯血5.3%。
- 气胸患者中68.3%(84/123)需置入胸管。
- 14.8%(69例)患者需移除支气管内活瓣。
- 住院中位时长2.8天(四分位距2.3-4.5天)。
- 住院死亡少于11例(<2.3%)。
- 发生住院并发症的亚组在合并症、人口学特征和医院特征方面与无并发症组无显著差异。
证据类型、等级与局限
- 证据类型:基于全国住院患者样本数据库的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,真实世界BLVR术后并发症率与早期随机对照试验相似,住院死亡率低,提示BLVR是重度肺气肿的安全治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early randomized controlled trials (RCTs) of bronchoscopic lung volume reduction (BLVR) have shown clinically meaningful benefits in lung function, dyspnea, and quality of life in patients with severe emphysema. Safety outcome data obtained after BLVR in the United States are scarce outside the RCTs.
RESEARCH QUESTION: What is the rate of inpatient complications after BLVR in the real world in the United States?
STUDY DESIGN AND METHODS: We used the National Inpatient Sample database to identify in-hospital complications after BLVR from 2018 through 2020. Complications were defined as pneumothorax, COPD exacerbation, pneumonia, hemoptysis, acute respiratory failure, and valve removal. We also analyzed all-cause in-hospital mortality and length of stay (LOS).
RESULTS: We identified 467 admissions related to BLVR procedures. The number of procedures doubled between 2019 and 2020 (from 153 to 295 procedures). The median age was 67.9 years (interquartile range, 61.1-72.8 years), 210 patients (45.0%) were female, 401 patients (85.8%) were White, and Medicare was the primary expected payer for 72.8% of patients. Most procedures were performed in urban teaching hospitals (56.9%). The rate of pneumothorax was 26.3%, that of acute respiratory failure was 19.5%, that of COPD exacerbation was 8.8%, that of pneumonia was 7.3%, and that of hemoptysis was 5.3%. Chest tube placement was required in 84 of 123 patients (68.3%) with pneumothorax. The endobronchial valve had to be removed in 69 patients (14.8%). The median LOS was 2.8 days (interquartile range, 2.3-4.5 days). The number of in-hospital deaths was fewer than 11 (< 2.3%). Overall, the subgroup who experienced in-hospital complications did not differ significantly from the others in terms of comorbidities, demographics, and hospital characteristics.
INTERPRETATION: We found that the real-world complication rate after BLVR was similar to the published complication rates from early randomized clinical trials. In-hospital mortality was low, suggesting that aside from the commonly anticipated complications, BLVR is a safe treatment option for severe emphysema.
参考来源
- Costa Filho FF, Buckley JD, Furlan A, et al. Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States. Chest. 2024. PMID: 39181376. doi:10.1016/j.chest.2024.08.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。